TL;DRAkeso’s ivonescimab reduced the risk of death by 34% in a phase three trial for squamous non-small cell lung cancer, with patients living nearly four months longer than those on the current standard therapy. The drug becomes the first Chinese-originated oncology treatment selected for ASCO’s plenary session in 61 years. Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the risk of death for patients with advanced squamous non-small cell lung cancer. The data, filed with the Hong Kong stock exchange on Monday and...